Takis' pipeline of genetic cancer vaccines and antibodies offers opportunities for co-development of our candidates. Our expertise in cancer immunotherapy also provides the basis for collaborations for the development of other vaccines.

We intend to bring our core vaccine candidates through to the completion of Phase Ib proof-of-concept trials. Selected immunotherapy candidates outside our core areas may be out-licensed at an earlier stage of development.

We are also seeking partnerships to support registration trials and market our veterinary vaccines worldwide.

Biopharmaceutical companies with a focus on Cancer and the clinical development of active immunotherapies can contact us to explore potential partnerships.

Contact us

Follow Us on Linkedin

Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity.